Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1983 1
2016 1
2017 1
2018 2
2019 3
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Dendriform Pulmonary Ossification.
Anan K, Hisanaga J, Kawamura K, Ichikado K. Anan K, et al. Among authors: hisanaga j. Intern Med. 2019 Apr 1;58(7):1043-1044. doi: 10.2169/internalmedicine.1764-18. Epub 2018 Dec 18. Intern Med. 2019. PMID: 30568141 Free PMC article. No abstract available.
Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia.
Ichikado K, Kawamura K, Johkoh T, Fujimoto K, Shintani A, Hashimoto S, Eguchi Y, Yasuda Y, Anan K, Shingu N, Sakata Y, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nishiyama K, Nakamura K, Suga M, Ichiyasu H, Sakagami T. Ichikado K, et al. Among authors: hisanaga j. Sci Rep. 2021 Oct 8;11(1):20051. doi: 10.1038/s41598-021-99540-1. Sci Rep. 2021. PMID: 34625618 Free PMC article.
Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. Sakata Y, et al. Among authors: hisanaga j. Thorac Cancer. 2019 Dec;10(12):2259-2266. doi: 10.1111/1759-7714.13214. Epub 2019 Nov 3. Thorac Cancer. 2019. PMID: 31679185 Free PMC article.
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. Sakata Y, et al. Among authors: hisanaga j. Lung Cancer. 2019 Apr;130:159-161. doi: 10.1016/j.lungcan.2019.02.011. Epub 2019 Feb 14. Lung Cancer. 2019. PMID: 30885338
Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
Hisanaga J, Kotani T, Fujiki Y, Yoshida S, Takeuchi T, Makino S. Hisanaga J, et al. Int J Rheum Dis. 2017 Dec;20(12):2182-2185. doi: 10.1111/1756-185X.13136. Epub 2017 Jul 27. Int J Rheum Dis. 2017. PMID: 28752606 No abstract available.